High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes

Journal of Internal Medicine

Volumn 271, Issue 1, 2012, Pages 82-89

  Engelbertsen, D ^a   Anand, D V ^b   Fredrikson, G N ^a,c   Hopkins, D ^d   Corder, R ^e   Shah, P K ^f,g   Lahiri, A ^b   Nilsson, J ^a   Bengtsson, E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b WELLINGTON HOSPITAL   (United Kingdom)

^c MALMÖ UNIVERSITY   (Sweden)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Autoantibodies; Diabetes

Indexed keywords

APOLIPOPROTEIN B100; CALCIUM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLGLYOXAL;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL OBSERVATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ELECTRON BEAM TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

APOLIPOPROTEIN B-100; AUTOANTIBODIES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PYRUVALDEHYDE; VASCULAR CALCIFICATION;

EID: 83855164160     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02411.x     Document Type: Article

References (27)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
2. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-46.
3. Soro-Paavonen A, Watson AM, Li J et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57: 2461-9.
4. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-69.
5. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-31.
6. Shibayama R, Araki N, Nagai R, Horiuchi S. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes 1999; 48: 1842-9.
7. Virella G, Thorpe SR, Alderson NL et al. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res 2003; 44: 487-93.
8. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-26.
9. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-19.
10. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 2008; 263: 464-78.
11. Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 2009; 50(Suppl.): S364-9.
12. Chou MY, Hartvigsen K, Hansen LF et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med 2008; 263: 479-88.
13. Schiopu A, Frendeus B, Jansson B et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007; 50: 2313-8.
14. Fredrikson GN, Anand DV, Hopkins D et al. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia 2009; 52: 1426-33.
15. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999; 48: 198-202.
16. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344(Pt 1): 109-16.
17. Cantero AV, Portero-Otin M, Ayala V et al. Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. FASEB J 2007; 21: 3096-106.
18. Fredrikson GN, Hedblad B, Berglund G et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 872-8.
19. Anand DV, Lim E, Hopkins D et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 2006; 27: 713-21.
20. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-7.
21. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003; 108: 2107-12.
22. Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006; 188: 160-6.
23. Chou MY, Fogelstrand L, Hartvigsen K et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119: 1335-49.
24. Witztum JL, Steinbrecher UP, Kesaniemi YA, Fisher M. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci U S A 1984; 81: 3204-8.
25. Lopes-Virella MF, McHenry MB, Lipsitz S et al. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007; 190: 359-69.
26. Tsimikas S, Brilakis ES, Lennon RJ et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 2007; 48: 425-33.
27. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 120: 417-26.